key: cord-1022476-mcc37ogt
authors: Bajpai, Divya; Shah, Deepal; Bose, Sreyashi; Deb, Satarupa; Gandhi, Chintan; Modi, Tulsi; Rao, Nikhil; Kumar, Kruteesh; Saxena, Nikhil; Katyal, Abhinav; Patil, Ankita; Thakare, Sayali; Pajai, Atim E.; Nataraj, Gita; Jamale, Tukaram E.
title: Development and longevity of antibodies against SARS‐CoV‐2 in kidney transplant recipients after symptomatic COVID‐19
date: 2021-06-01
journal: Transpl Infect Dis
DOI: 10.1111/tid.13646
sha: 197a6c7d9ee750cf3a7cde017c76098619601919
doc_id: 1022476
cord_uid: mcc37ogt

The development and longevity of antibodies against SARS-CoV-2 in kidney transplant recipients (KTRs) is not clear. Though seroconversion has been documented1 , the persistence of this response with time is not established. We longitudinally studied the presence of anti-SARS-CoV-2 IgG antibodies in KTRs after symptomatic coronavirus disease-2019 (COVID-19). Forty-seven patients with a positive SARS-CoV-2 RTPCR between May 2020 and March 2021 were followed up in the transplant clinic for 5.55 ± 2.32 months. Sera was initially tested at day 15 from diagnosis for the presence of anti-SARS-CoV-2 total IgG antibodies using COVID KAWACH IgG MICROLISA (J. Mitra Pvt. Ltd; approved by the Indian Council of Medical Research2 ). It is a qualitative assay using SARS CoV-2 virus whole-cell antigen (sensitivity = 96.33%, specificity = 100%). Patients negative on day 15, were retested until they seroconverted.

To the editors, (Table S1 ).

Patients with positive IgG were repeatedly tested at an interval 

All authors declare that they have no conflict of interests.

All the authors have positively contributed to the study. The study was designed by DB and TEJ. DS, SD, SB, CG, TM, KK, NR, AK, NS, AP, ST, and AEP, were involved in the data collection and performance of the study. DS and GN were involved in conducting the laboratory tests. DB and TEJ did the data analysis. DB and TEJ prepared the manuscript. Final manuscript was read and approved by all the authors.

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Detection of SARS-CoV-2 antibodies in kidney transplant recipients

Decline and loss of anti-SARS-CoV-2 antibodies in kidney transplant recipients in the 6 months following SARS-CoV-2 infection

Loss of anti-SARS-CoV-2 antibodies in mild Covid-19

Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild Covid-19 [published correction appears in

https://orcid.org/0000-0003-2294-0506